S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Critical asset just had biggest fall on record (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Critical asset just had biggest fall on record (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Critical asset just had biggest fall on record (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Critical asset just had biggest fall on record (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Critical asset just had biggest fall on record (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Critical asset just had biggest fall on record (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Critical asset just had biggest fall on record (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Critical asset just had biggest fall on record (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Critical asset just had biggest fall on record (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Dell Technologies breaks out ahead of earnings release
Critical asset just had biggest fall on record (Ad)
Dropbox’s stock is a falling knife worth catching
Novavax’s dispute resolution and upcoming earnings call
Critical asset just had biggest fall on record (Ad)
Stock ideas from the 2024 Microcap Conference
Warner Bros. Discover: Debt down, profits up, yet questions remain
Critical asset just had biggest fall on record (Ad)
Gloom settles over Germany's economy, with businesses downbeat about the coming months
Sprouts, Block rise; Booking Holdings, Insulet fall, Friday, 2/23/2024
NASDAQ:CBAY

CymaBay Therapeutics (CBAY) Stock Price, News & Analysis

$32.23
+0.06 (+0.19%)
(As of 02/23/2024 ET)
Today's Range
$32.18
$32.26
50-Day Range
$22.18
$32.23
52-Week Range
$7.26
$32.26
Volume
2.90 million shs
Average Volume
4.47 million shs
Market Capitalization
$3.65 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.73

CymaBay Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.15 Rating Score
Upside/​Downside
17.1% Downside
$26.73 Price Target
Short Interest
Healthy
8.20% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.88
Upright™ Environmental Score
News Sentiment
0.66mentions of CymaBay Therapeutics in the last 14 days
Based on 15 Articles This Week
Insider Trading
Selling Shares
$3.37 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.95) to ($1.34) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.59 out of 5 stars

Medical Sector

276th out of 941 stocks

Pharmaceutical Preparations Industry

119th out of 428 stocks


CBAY stock logo

About CymaBay Therapeutics Stock (NASDAQ:CBAY)

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary biliary cholangitis (PBC). The company also develops MBX-2982 for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

CBAY Stock Price History

CBAY Stock News Headlines

Analysts see over 50% gains in these 2 mid-cap biotech stocks (CBAY)
The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs.
Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
CBAY Jan 2026 37.000 call
CymaBay Therapeutics (NASDAQ:CBAY) Rating Reiterated by B. Riley
CymaBay Therapeutics (NASDAQ:CBAY) Downgraded by William Blair
CBAY Feb 2024 33.000 call
See More Headlines
Receive CBAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CymaBay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
2/24/2024
Next Earnings (Estimated)
3/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CBAY
Employees
60
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$26.73
High Stock Price Target
$32.50
Low Stock Price Target
$12.00
Potential Upside/Downside
-17.1%
Consensus Rating
Hold
Rating Score (0-4)
2.15
Research Coverage
13 Analysts

Profitability

Net Income
$-106,000,000.00
Pretax Margin
-290.50%

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.43 per share

Miscellaneous

Free Float
105,462,000
Market Cap
$3.65 billion
Optionable
Optionable
Beta
0.28

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives















CBAY Stock Analysis - Frequently Asked Questions

Should I buy or sell CymaBay Therapeutics stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last twelve months. There are currently 11 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CBAY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CBAY, but not buy additional shares or sell existing shares.
View CBAY analyst ratings
or view top-rated stocks.

What is CymaBay Therapeutics' stock price target for 2024?

13 Wall Street research analysts have issued 12 month price objectives for CymaBay Therapeutics' stock. Their CBAY share price targets range from $12.00 to $32.50. On average, they anticipate the company's stock price to reach $26.73 in the next year. This suggests that the stock has a possible downside of 17.1%.
View analysts price targets for CBAY
or view top-rated stocks among Wall Street analysts.

How have CBAY shares performed in 2024?

CymaBay Therapeutics' stock was trading at $23.62 on January 1st, 2024. Since then, CBAY stock has increased by 36.5% and is now trading at $32.23.
View the best growth stocks for 2024 here
.

Are investors shorting CymaBay Therapeutics?

CymaBay Therapeutics saw a drop in short interest during the month of January. As of January 31st, there was short interest totaling 9,300,000 shares, a drop of 7.6% from the January 15th total of 10,070,000 shares. Based on an average trading volume of 1,710,000 shares, the days-to-cover ratio is presently 5.4 days.
View CymaBay Therapeutics' Short Interest
.

When is CymaBay Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our CBAY earnings forecast
.

How were CymaBay Therapeutics' earnings last quarter?

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) posted its quarterly earnings data on Tuesday, November, 7th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.02. During the same quarter in the prior year, the firm posted ($0.28) EPS.

What other stocks do shareholders of CymaBay Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Advanced Micro Devices (AMD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA), Novavax (NVAX), Corbus Pharmaceuticals (CRBP), Energy Transfer (ET) and Viking Therapeutics (VKTX).

Who are CymaBay Therapeutics' major shareholders?

CymaBay Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Avoro Capital Advisors LLC (9.80%), Vanguard Group Inc. (5.56%), Price T Rowe Associates Inc. MD (3.94%), Price T Rowe Associates Inc. MD (3.94%), Jennison Associates LLC (3.52%) and Franklin Resources Inc. (2.88%). Insiders that own company stock include Charles Mcwherter, Daniel Menold, Dennis D Kim, Janet Dorling, Kurt Von Emster, Paul T Quinlan and Sujal Shah.
View institutional ownership trends
.

How do I buy shares of CymaBay Therapeutics?

Shares of CBAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CBAY) was last updated on 2/24/2024 by MarketBeat.com Staff